The medication is generally used to provide supportive, systemic symptomatic relief for conditions arising from the body's heightened response to allergens, particularly in clinical situations marked by recurrent or persistent distress.

Xuzal is applied across therapeutic domains where additional symptomatic support is needed, and is commonly used for two categories of conditions: seasonal and perennial allergic rhinitis (hay fever and year-round allergies) and Chronic Idiopathic Urticaria (hives). It helps manage symptom clusters related to inflammatory or irritative states, such as frequent sneezing, persistent runny nose, itchy eyes, and the appearance of recurring wheals on the skin. This supportive relief may assist with maintaining a sense of stability when symptoms are more noticeable.

“It is relevant in contexts involving heightened systemic burden, and may assist with maintaining a sense of stability.”

Quick Fact: Relief for Skin Pruritus and Nasal Discomfort The medicine is used for managing symptom clusters that may become more noticeable or disruptive, contributing to easing the overall symptom load during periods of heightened physical discomfort.

Regulatory References

1. Levocetirizine: MedlinePlus Drug Information

Who Can and Cannot Use Xuzal?

Eligibility for Xuzal (levocetirizine) is determined by regulatory agencies based on age, kidney function, and known allergies. This information defines who is officially approved to use the medicine and who must not.

Populations Excluded from Use (Contraindications)

Classification	Rule (Source: Regulatory Labels)
Hypersensitivity	Must not be used by patients with a known allergy to levocetirizine, any of its ingredients, or to cetirizine or other piperazine derivatives (e.g., hydroxyzine).
Severe Renal Impairment	Contraindicated in adults with End-Stage Renal Disease ( CL CR < 10 mL/min) and in children 6 months to 11 years with any degree of renal impairment.

Age-Specific Eligibility

• Adults and Adolescents (ge 12 years) are approved for use.
• Children 6 to 11 years are eligible, though the tablet formulation is generally not recommended for those under 6 years.
• The Oral Solution has established use in U.S. labeling for infants as young as 6 months for certain indications. However, administration to children under 2 years is not recommended in the EU due to insufficient data.

Special Considerations

Patients with mild to moderate renal impairment require a dose adjustment. Caution is advised for patients with a predisposing factor for urinary retention or those with a history of epilepsy due to the risk of convulsion aggravation. Use during pregnancy may be considered if clearly needed, but it is not recommended while breastfeeding.

Interactions with other medicines and products

Official regulatory information describes the documented interaction patterns for Xuzal (Levocetirizine), primarily focusing on pharmacodynamic additive effects, pharmacokinetic changes in clearance, and administration constraints.

Documented Interaction Patterns

Interaction Type	Interacting Substance	Official Outcome
Pharmacodynamic	Alcohol / CNS Depressants	Potential for additive impairment of central nervous system (CNS) performance and reduction in alertness; concurrent use should be avoided.
Pharmacokinetic	Ritonavir	Documented to increase plasma exposure (AUC) of the drug's parent compound (cetirizine) and reduce clearance.
Pharmacokinetic	Theophylline	Documented to cause a minor decrease in clearance of the drug's parent compound (cetirizine) at specific doses.
Absorption/Food	Food (Meals)	Does not reduce the extent of absorption (AUC), but delays the time to peak concentration (Tmax) and reduces the maximum concentration (Cmax) by approximately 36 percent.

Interaction-Related Restrictions

Use of Levocetirizine is formally contraindicated in individuals with End-Stage Renal Disease (eGFR less than 15 mL/min) due to the drug's substantial dependence on renal excretion for elimination. Additionally, official in vitro data indicates the medicine is unlikely to cause pharmacokinetic interactions through inhibition or induction of major liver drug-metabolizing enzymes (CYP450). Dose adjustment is also required for elderly patients with moderate to severe renal impairment.

Selective Blockade of the Peripheral Histamine mathbfH1 -Receptor

Levocetirizine's core molecular action is the selective antagonism of the Histamine mathbfH1 -receptor found in peripheral tissues. By blocking this receptor with high affinity, the drug disrupts the histamine-mediated signaling cascade. This physiologically leads to the inhibition of increased capillary permeability and reduction of histamine-mediated sensory nerve stimulation. This targeted peripheral action, coupled with minimal blood-brain barrier penetration, ensures the effect is concentrated on peripheral histamine and associated pathways, avoiding significant central H1 -receptor blockade.

---

Modulation of Inflammatory Cell Recruitment Pathways

Beyond direct antagonism, Levocetirizine acts on the cellular inflammatory response. The mechanism involves engaging processes that inhibit the expression of adhesion molecules (like ICAM-1) on endothelial surfaces, which functionally reduces the chemotaxis (migration) of eosinophils into tissues. This pathway adjustment modulates signaling within the cellular cascade, resulting in the inhibition of eosinophil accumulation at targeted sites.

The administration of levocetirizine (Xuzal) is restricted to the oral route, utilizing the available 5 mg film-coated tablets or the 0.5 mg/mL oral solution. The standardized regimen for adults and adolescents aged 12 years requires a dose of 5 mg taken once daily, typically administered in the evening in a single intake. The required 5 mg daily dose can be taken without regard to food consumption.

For children, a lower maximum daily dose is specified: 2.5 mg for those aged 6 to 11 years, and 1.25 mg for children 6 months to 5 years. Dosage modification is necessary based on a patient's kidney function, as the drug is primarily eliminated by the kidneys. For adults with mild or moderate renal impairment, a reduced dose or reduced frequency is required according to the estimated creatinine clearance. The administration of the medicine is contraindicated in patients with end-stage renal disease (creatinine clearance < 10 mL/min). For missed timing, the general procedural rule is to skip the forgotten dose and resume the single-dose schedule at the next designated time.

Research Evidence: Overview of Studies for Xuzal (Levocetirizine)

The information below summarizes the clinical research conducted for levocetirizine, focusing on the types of studies that have been used for regulatory evaluation. This overview describes the research landscape and what study findings typically report, and it does not offer any medical advice or instruction.

---

Evidence for Use in Seasonal Allergic Rhinitis (SAR)

The research into seasonal allergic rhinitis, commonly known as hay fever, has been primarily conducted through short-term, randomized controlled trials (RCTs). These studies are relevant in trials assessing short-term or episodic symptom patterns and were conducted during periods of increased symptom activity, such as a local pollen season.

Studies were evaluated in populations including adults, adolescents, and children as young as one year of age who experienced documented seasonal allergies. The main outcomes measured were the change in composite scores that combine the severity of common allergy symptoms, such as sneezing, runny nose, itchy eyes, and nasal irritation. However, the primary evidence for seasonal symptom patterns is often derived from studies with follow-up durations that were limited to approximately two to four weeks.

---

Evidence for Use in Perennial Allergic Rhinitis (PAR)

The evaluation for year-round allergic rhinitis included large, long-term, randomized, placebo-controlled trials designed to explore the use of levocetirizine in conditions characterized by fluctuating manifestations over extended periods. Research examined adults and adolescents with persistent allergic rhinitis, focusing on outcomes reflecting daily functioning or activity level.

Long-term trials tracked and reported symptom score measurements over a period of up to six months. Findings describe patterns observed in these extended studies that explored nasal symptoms, including nasal congestion, and assessed functional measures such as sleep quality.

---

Evidence for Use in Chronic Hives (Chronic Idiopathic Urticaria, CIU)

The research for chronic idiopathic urticaria (hives without a known cause) was evaluated in short-term, placebo-controlled RCTs, often followed by supplementary, longer observational cohort studies. Primary outcomes measured the change in both objective skin signs and subjective distress, specifically the severity score of itching (pruritus), the number of visible wheals, and the size of wheals.

---

What is Still Uncertain About Xuzal Research

The evidence landscape contains areas where data are still emerging. The main limitations often acknowledged in the scientific literature include that follow-up durations were limited for many pivotal efficacy trials, especially for research into chronic hives and continuous use across consecutive allergy seasons. Comparative evidence is limited when examining the medicine against a full spectrum of other available non-sedating antihistamines using a completely standardized methodology.

Key Studies & References

1. Levocetirizine for the Treatment of Allergic Rhinitis and Chronic Idiopathic Urticaria in Adults and Children (Systematic Review)

Common questions about Xuzal (FAQ)

Q: What is Xuzal and how does it work?

A: Xuzal (levocetirizine) is an antihistamine used to relieve symptoms of:

• Seasonal and perennial allergic rhinitis (e.g., runny nose, sneezing, watery eyes, itching of the nose or throat).
• Chronic idiopathic urticaria (long-term hives without a known cause).

It works by blocking the effects of histamine, a substance the body releases during an allergic reaction. This action helps to reduce allergy and hive symptoms.

Q: How quickly does Xuzal start working?

A: Xuzal generally starts to work quickly, usually within about one hour after taking a dose.

Q: What are the most common side effects of Xuzal?

A: The most commonly reported side effects include:

• Drowsiness or sleepiness (somnolence)
• Fatigue or tiredness
• Dry mouth
• Inflammation of the nose and throat (nasopharyngitis)

Q: Can Xuzal cause drowsiness?

A: Yes, Xuzal can cause drowsiness, sleepiness, or fatigue. While it is often considered a low-sedating antihistamine, it may affect alertness in some people.

Patients should be cautious about performing activities requiring full mental alertness, such as driving or operating machinery, until they know how Xuzal affects them.

Q: Is it safe to drink alcohol while taking Xuzal?

A: Alcohol should be avoided while taking Xuzal. The combination of alcohol with Xuzal can increase the risk of reduced alertness and further impair central nervous system performance, amplifying the effects of drowsiness.

Q: Can Xuzal cause serious side effects?

A: While rare, some serious side effects have been reported. You should seek medical attention immediately if you experience signs of an allergic reaction (such as swelling of the face, tongue, or throat, or trouble breathing) or other serious symptoms such as:

• Urinary retention (difficulty emptying the bladder or a decrease in urine volume)
• Seizures or an increase in the frequency of existing seizures
• Thoughts of self-harm or suicidal ideation
• Severe, widespread itching (pruritus) that occurs after stopping the medicine following long-term use (typically for a few months or more).

Q: Does Xuzal interact with other medications?

A: Xuzal may interact with other medications, especially those that affect the central nervous system, such as sedatives or tranquilizers, and other CNS depressants, which can increase the risk of drowsiness. Always inform your healthcare professional about all the medicines and supplements you are taking.

How to Store and Dispose of Xuzal (Levocetirizine Dihydrochloride)

Official labeling requires specific conditions for the storage and disposal of Xuzal to maintain product quality and safety.

---

Storage Requirements

Xuzal must be stored at Controlled Room Temperature, between 20°C to 25°C (68°F to 77°F). It is mandatory to keep the medicine in its original container with the cap tightly closed and protected from excessive heat and moisture. A critical requirement is to store the product out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Do not flush unused or expired Xuzal down the toilet or pour it into a drain. The preferred method is to utilize a community drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance, placed in a sealed bag, and discarded in the household trash, following regulatory guidelines.